ClinicalTrials.gg
CompletedNCT00565448Updated Jul 30, 2015Results posted

Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

A Phase 2 interventional study of docetaxel and cisplatin in Nasopharyngeal Neoplasms and Carcinoma, sponsored by Sanofi. Completed at 26 sites in 14 countries. Open to participants aged 1 Month to 21 Years. Per ClinicalTrials.gov, last updated 2015-07-30.

Primary conditionNasopharyngeal CarcinomaRegistry: Nasopharyngeal NeoplasmsReclassifiedWhy we changed it
Registry
Nasopharyngeal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasopharyngeal Carcinoma
Why
  1. The study's title name Nasopharyngeal Carcinoma, a narrower term within Nasopharyngeal Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
1 Month to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing docetaxel in Nasopharyngeal Carcinoma — 1 open to participants now, 4 under way, 3 of them phase 3. Docetaxel · Nasopharyngeal Carcinoma.

Enrollment
11th of 17
75 · median 130
Started
2007
with 2 others
Phase 2
9 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
1 of 17
Sanofi

Among the 17 studies testing docetaxel in Nasopharyngeal Carcinoma, this one is the 11th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 2, and was the 1st registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

1 of the 17 studies testing docetaxel in Nasopharyngeal Carcinoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 1 Month to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing docetaxel in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma (NPC).

The secondary objectives are to determine:

  • the safety of TCF in comparison to CF after induction treatment of NPC,
  • the pharmacokinetics of docetaxel when added to CF,
  • the Overall Response rate of TCF and CF on completion of induction and consolidation (chemo-radiotherapy) treatment of NPC, and to compare overall survival between TCF and CF.
Read the detailed description

Planned treatment duration:

  • induction period: 9 weeks of induction treatment
  • consolidation period: 9 weeks of chemoradiation treatment.

The consolidation treatment was the same for all participants: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.

03

Conditions studied

  • Nasopharyngeal Neoplasms
  • Carcinoma

Browse trials for

Keywords

  • Nasopharyngeal carcinoma
04

In context

Nasopharyngeal Carcinoma Reclassified

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

This study's enrollment of 75 is below the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.

Browse Nasopharyngeal Carcinoma studies →

Lead sponsor

Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Compared within Nasopharyngeal Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nasopharyngeal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Month to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of nasopharyngeal carcinoma World Health Organization (WHO) type II or III
  • Children and adolescents newly diagnosed with Stage IIB-IV NPC with , who are >1 month to ≤21 years of age at the time of diagnosis. In France, participants must be ≥1 year to ≤21 years of age at the time of diagnosis

Exclusion criteria

Exclusion Criteria:

  • Participants with short
  • Prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma
  • Inadequate renal function evidenced by unacceptable laboratory results

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Docetaxel/Cisplatin/5-FU (TCF)

    * Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks * Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks * 5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.

    Drug: docetaxel · Drug: cisplatin · Drug: 5-fluorouracil

  • Active comparator
    Cisplatin/5-FU (CF)

    * Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks * 5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy. Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks.

    Drug: cisplatin · Drug: 5-fluorouracil

Interventions

  • Pharmaceutical form:solution for infusion Route of administration:intravenous

    Also known as: Taxotere®, XRP6976

  • Pharmaceutical form:solution for infusion Route of administration:intravenous

  • Pharmaceutical form:solution for infusion Route of administration:intravenous

    Also known as: 5-FU

07

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Response (CR)

    CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the induction treatment and prior to the radiation treatment. CR defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.

    Time frame: after the completion of the induction treatment (up to 9 weeks)

Secondary outcomes

  1. Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group

    AUC estimated by Bayesian method using concentration-time data for each participant and the previously defined adult population model as prior information (with validity of the estimation verified).

    Time frame: Three plasma samples: one just before then 45 minutes and 5hour after the end of cycle 1 infusion

  2. Overall Response (OR)

    OR is classified as CR, partial response (PR), stable disease (SD), progressive disease (PD) or Unknown on completion of both induction and radiation treatment and assessed according to the Modified RECIST from the NCI. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as ≥30% decrease in the sum of the longest diameters (LD) of TLs, taking as reference the disease measurement done at study entry. PD is defined as ≥20% increase in the sum of the LD of TLs, taking as a reference the smallest disease measurement recorded at study entry or the appearance of ≥1 new lesions or unequivocal progression of non-TLs. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: after the completion of the consolidation treatment (up to 18 weeks)

  3. Overall Survival (OS) Rate

    OS rate is the percentage of participants who survived 3 years after completion of consolidation treatment period. The Kaplan-Meier method was used to estimate OS rate.

    Time frame: 3 years after the end of the consolidation treatment period (up to 40 months from randomization)

08

Results

Posted Mar 25, 2010

Participant flow

Participants were enrolled from November 2007 until October 2008. The study was conducted at 26 centers in 14 countries.

Participant flow — Overall Study
MilestoneDocetaxel /Cisplatin/5-FUCisplatin/5-FU
Started5025
Completed4723
Not completed32
Withdrew: Adverse event12
Withdrew: Disease progression10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Participants With Complete Response (CR)

CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI). Disease response evaluated after the completion of the induction treatment and prior to the radiation treatment. CR defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only.

Time frame:
after the completion of the induction treatment (up to 9 weeks)
Reported as:
Number · participants
Number of Participants With Complete Response (CR)
participantsDocetaxel /Cisplatin/5-FUCisplatin/5-FU
Number of Participants With Complete Response (CR)10
Statistical analysis
  • Docetaxel /Cisplatin/5-FU vs Cisplatin/5-FU · Fisher Exact · p = 1.0000 (The Fisher's exact test was used to compare the CR proportions.)
SecondaryDocetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group

AUC estimated by Bayesian method using concentration-time data for each participant and the previously defined adult population model as prior information (with validity of the estimation verified).

Time frame:
Three plasma samples: one just before then 45 minutes and 5hour after the end of cycle 1 infusion
Reported as:
Mean · µg*h/mL
Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group
µg*h/mLDocetaxel/Cisplatin/5-FU
Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group3.43 ± 2.05
SecondaryOverall Response (OR)

OR is classified as CR, partial response (PR), stable disease (SD), progressive disease (PD) or Unknown on completion of both induction and radiation treatment and assessed according to the Modified RECIST from the NCI. CR is defined as the disappearance of all target lesions (TLs) and non-TLs. PR is defined as ≥30% decrease in the sum of the longest diameters (LD) of TLs, taking as reference the disease measurement done at study entry. PD is defined as ≥20% increase in the sum of the LD of TLs, taking as a reference the smallest disease measurement recorded at study entry or the appearance of ≥1 new lesions or unequivocal progression of non-TLs. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
after the completion of the consolidation treatment (up to 18 weeks)
Reported as:
Number · participants
Overall Response (OR)
participantsDocetaxel /Cisplatin/5-FUCisplatin/5-FU
CR11
PR4320
SD21
PD20
Unknown00
Missing23
SecondaryOverall Survival (OS) Rate

OS rate is the percentage of participants who survived 3 years after completion of consolidation treatment period. The Kaplan-Meier method was used to estimate OS rate.

Time frame:
3 years after the end of the consolidation treatment period (up to 40 months from randomization)
Reported as:
Number · percentage of participants
Overall Survival (OS) Rate
percentage of participantsDocetaxel /Cisplatin/5-FUCisplatin/5-FU
Overall Survival (OS) Rate85.7 (75.9 to 95.5)78.0 (60.8 to 95.1)

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cisplatin/5-FU—11/25 (44%)23/25 (92%)
Docetaxel /Cisplatin/5-FU—20/50 (40%)49/50 (98%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventCisplatin/5-FUDocetaxel /Cisplatin/5-FU
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/255/50
NEUTROPENIA/NEUTROPHIL COUNTBlood and lymphatic system disorders2/254/50
CONVULSIONNervous system disorders2/251/50
DIARRHOEAGastrointestinal disorders0/253/50
ANOREXIAMetabolism and nutrition disorders0/253/50
BONE MARROW FAILUREBlood and lymphatic system disorders1/250/50
FEBRILE BONE MARROW APLASIABlood and lymphatic system disorders1/250/50
LEUKOPENIABlood and lymphatic system disorders1/250/50
THROMBOCYTOPENIABlood and lymphatic system disorders1/250/50
STOMATITISGastrointestinal disorders1/252/50
Most frequent other events
Showing 10 of 57
Most frequent other events
EventCisplatin/5-FUDocetaxel /Cisplatin/5-FU
VOMITINGGastrointestinal disorders21/2547/50
NAUSEAGastrointestinal disorders10/2533/50
STOMATITISGastrointestinal disorders5/2530/50
ALOPECIASkin and subcutaneous tissue disorders1/2529/50
ANOREXIAMetabolism and nutrition disorders5/2521/50
NEUTROPENIA/NEUTROPHIL COUNTBlood and lymphatic system disorders7/2520/50
WEIGHT DECREASEDInvestigations8/2520/50
DIARRHOEAGastrointestinal disorders3/2515/50
ANAEMIABlood and lymphatic system disorders3/2514/50
DYSPHAGIAGastrointestinal disorders7/2512/50

Baseline characteristics

ITT population: all randomized participants.

Age, Continuous
Age, Continuous(years)Docetaxel /Cisplatin/5-FUCisplatin/5-FUTotal
Median16 (9 to 21)16 (9 to 21)16 (9 to 21)
Age, Customized
Age, Customized(participants)Docetaxel /Cisplatin/5-FUCisplatin/5-FUTotal
Infants from 28 days to 23 months000
Children from 2 years to <12 years415
Adolescents from 12 years to <16 years201030
Adolescents >=16261440
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel /Cisplatin/5-FUCisplatin/5-FUTotal
Female15621
Male351954
09

Study locations

26 sites
  • Investigational Site Number 012001
    Alger, 16005, Algeria
  • Investigational Site Number 076002
    Rio De Janeiro, 20230-130, Brazil
  • Investigational Site Number 076001
    Sao Paulo, 04023-062, Brazil
  • Investigational Site Number 156005
    Fuzhou, 350014, China
  • Investigational Site Number 250001
    Villejuif Cedex, 94805, France
  • Investigational Site Number 356003
    Ahmedabad, 380006, India
  • Investigational Site Number 356004
    Kolkata, 700054, India
  • Investigational Site Number 356002
    Thiruvananthapuram, 695011, India
  • Investigational Site Number 356001
    Vellore, 632004, India
  • Investigational Site Number 360001
    Jakarta, 10430, Indonesia
  • Investigational Site Number 380001
    Milano, 20133, Italy
  • Investigational Site Number 410001
    Seoul, 110-744, Korea, Republic of
  • Investigational Site Number 410003
    Seoul, 135-710, Korea, Republic of
  • Investigational Site Number 410002
    Seoul, 138-736, Korea, Republic of
  • Investigational Site Number 484001
    Villahermosa, 86100, Mexico
  • Investigational Site Number 504001
    Casablanca, 20000, Morocco
  • Investigational Site Number 504002
    Rabat, 10000, Morocco
  • Investigational Site Number 504003
    Rabat, Morocco
  • Investigational Site Number 608002
    Quezon City, Philippines
  • Investigational Site Number 764001
    Bangkok, 10330, Thailand
  • Investigational Site Number 764002
    Chiang Mai, 50200, Thailand
  • Investigational Site Number 788002
    Sousse, 4000, Tunisia
  • Investigational Site Number 788003
    Tunis, 1006, Tunisia
  • Investigational Site Number 792003
    Abacioglu, 34662, Turkey
  • Investigational Site Number 792001
    Ankara, 06100, Turkey
  • Investigational Site Number 792002
    Istanbul, 34303, Turkey
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Mar 2009 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2007
First posted
Nov 30, 2007
Start
Nov 2007
Primary completionActual
Mar 2009
CompletionActual
Jan 2012
Results first posted
Mar 25, 2010
Last update
Jul 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00565448
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 30, 2007
Start date
Nov 2007
Primary completion
Mar 2009
Completion
Jan 2012
Results posted
Mar 25, 2010
Last update
Jul 30, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion